Literature DB >> 23714111

Stimulated human peripheral T cells produce high amounts of IL-35 protein in a proliferation-dependent manner.

Karina Guttek1, Dirk Reinhold.   

Abstract

The p35 subunit of IL-12 and the Epstein-Barr virus-induced gene 3 (EBI3) have been shown to form a heterodimeric cytokine, named interleukin-35 (IL-35). Recently, mRNA expression of both IL-12p35 and EBI3 was clearly shown in stimulated human T effector cells. Here, we investigated the production of IL-35 protein in human anti-CD3/CD28-stimulated pan T cells as well as T cell subpopulations using a specific human IL-35 ELISA system. We measured high concentrations of IL-35 (up to 3 ng/ml) in cell culture supernatants of stimulated pan T cells as well as CD4(+), CD8(+) and CD4(+)CD25(-) T cell subpopulations at 72 h after stimulation. Very low amounts of IL-35, in the range of 100pg/ml, were detectable in supernatants of resting T cells. These observations could be confirmed using a dot-blot assay for IL-12p35 and EBI3. High concentrations of IL-35 could be also measured in cell culture supernatants of both, resting and stimulated CD4(+)CD25(+) T cells. In order to learn more about the regulation of IL-35 production, we studied the effect of dexamethasone, cyclosporine A and rapamycin on IL-35 production of anti-CD3/CD28-stimulated human pan T cells as well as CD4(+) and CD8(+) T cell subpopulations. All three drugs significantly suppressed IL-35 production of these cells in a proliferation-dependent manner. In summary, we could show that stimulated human peripheral blood T cells of healthy donors produce high amounts of IL-35 protein. However, the biological function of this cytokine remains to be elucidated.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cyclosporine A; Dexamethasone; EBI3; ELISA; Epstein–Barr virus-induced gene 3; FoxP3; IL; IL-35; PBMC; Stimulated human T cells; TGF-ß; forkhead box P3; interleukin; peripheral blood mononuclear cells; transforming growth facor-beta

Mesh:

Substances:

Year:  2013        PMID: 23714111     DOI: 10.1016/j.cyto.2013.04.037

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  7 in total

1.  Elevated serum IL-35 and increased expression of IL-35-p35 or -EBI3 in CD4(+)CD25(+) T cells in patients with active tuberculosis.

Authors:  Bin Kong; Gan-Bin Liu; Jun-Ai Zhang; Xiao-Xia Fu; Wen-Yu Xiang; Yu-Chi Gao; Yuan-Bin Lu; Xian-Jing Wu; Feng Qiu; Wan-Dang Wang; Lai-Long Yi; Ji-Xin Zhong; Zheng W Chen; Jun-Fa Xu
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

2.  Contribution of IL-12/IL-35 common subunit p35 to maintaining the testicular immune privilege.

Authors:  Hayato Terayama; Takayuki Yoshimoto; Shuichi Hirai; Munekazu Naito; Ning Qu; Naoyuki Hatayama; Shogo Hayashi; Kana Mitobe; Jun-Ichi Furusawa; Izuru Mizoguchi; Takeshi Kezuka; Hiroshi Goto; Kaori Suyama; Hiroshi Moriyama; Kou Sakabe; Masahiro Itoh
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

Review 3.  Interleukin-12 family cytokines and sarcoidosis.

Authors:  Sabine Ringkowski; Paul S Thomas; Cristan Herbert
Journal:  Front Pharmacol       Date:  2014-10-27       Impact factor: 5.810

4.  Interleukin-35-Producing CD8α+ Dendritic Cells Acquire a Tolerogenic State and Regulate T Cell Function.

Authors:  Sergio Haller; Anaïs Duval; Romain Migliorini; Mathias Stevanin; Vanessa Mack; Hans Acha-Orbea
Journal:  Front Immunol       Date:  2017-02-08       Impact factor: 7.561

Review 5.  Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent.

Authors:  Peng Gao; Zhenzhong Su; Xuejiao Lv; Jie Zhang
Journal:  Mediators Inflamm       Date:  2017-04-30       Impact factor: 4.711

Review 6.  Interleukin-35 in autoimmune dermatoses: Current concepts.

Authors:  Yuming Xie; Huilin Zhang; Junke Huang; Qing Zhang
Journal:  Open Med (Wars)       Date:  2022-03-21

Review 7.  Interactions between Autophagy and Inhibitory Cytokines.

Authors:  Tian-Tian Wu; Wei-Min Li; Yong-Ming Yao
Journal:  Int J Biol Sci       Date:  2016-06-07       Impact factor: 6.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.